These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 24874200)

  • 41. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
    Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction.
    Rich JD; Burns J; Freed BH; Maurer MS; Burkhoff D; Shah SJ
    J Am Heart Assoc; 2018 Oct; 7(20):e009594. PubMed ID: 30371285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
    Swedberg K; Pfeffer M; Granger C; Held P; McMurray J; Ohlin G; Olofsson B; Ostergren J; Yusuf S
    J Card Fail; 1999 Sep; 5(3):276-82. PubMed ID: 10496201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.
    Di Tullio MR; Qian M; Thompson JL; Labovitz AJ; Mann DL; Sacco RL; Pullicino PM; Freudenberger RS; Teerlink JR; Graham S; Lip GY; Levin B; Mohr JP; Buchsbaum R; Estol CJ; Lok DJ; Ponikowski P; Anker SD; Homma S;
    Stroke; 2016 Aug; 47(8):2031-7. PubMed ID: 27354224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
    Shah KS; Xu H; Matsouaka RA; Bhatt DL; Heidenreich PA; Hernandez AF; Devore AD; Yancy CW; Fonarow GC
    J Am Coll Cardiol; 2017 Nov; 70(20):2476-2486. PubMed ID: 29141781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
    Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.
    Dewan P; Rørth R; Raparelli V; Campbell RT; Shen L; Jhund PS; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; O'Meara E; Pfeffer MA; Pitt B; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    Circ Heart Fail; 2019 Dec; 12(12):e006539. PubMed ID: 31813280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.
    Mogensen UM; Jhund PS; Abraham WT; Desai AS; Dickstein K; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Køber L; McMurray JJV;
    J Am Coll Cardiol; 2017 Nov; 70(20):2490-2500. PubMed ID: 29145948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
    Damman K; Solomon SD; Pfeffer MA; Swedberg K; Yusuf S; Young JB; Rouleau JL; Granger CB; McMurray JJ
    Eur J Heart Fail; 2016 Dec; 18(12):1508-1517. PubMed ID: 27427441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
    Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
    Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.